Overview

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Status:
Completed
Trial end date:
2018-08-16
Target enrollment:
Participant gender:
Summary
The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim